Cambrooke Therapeutics, Inc., said it has been acquired by Ajinomoto Co. Inc., a procducer of amino acids, pharmaceuticals, high-quality seasonings, processed foods, beverages, and specialty chemicals, through its subsidiary Ajinomoto North America, Inc.
Prior to the acquisition, Cambrooke was a privately-held business led by investors Galen Partners and Seventure Partners.
Cambrooke’s product portfolio serves the needs of people with chronic health conditions reliant on medical foods and specialized functional foods as a central part of their daily nutritional needs. With this acquisition, Cambrooke gains access to Ajinomoto’s global nutrition and ingredient sciences expertise, as well as proven flavor and texture-enhancing R&D capabilities.
For many decades Ajinomoto has contributed to global health and wellness through wide-ranging specialty applications of amino acid technologies. Today, the company is becoming increasingly involved in creating solutions for specialty nutrition, improved food resources and global sustainability. Ajinomoto’s acquisition of Cambrooke supports Cambrooke’s focus on specialty nutrition and enables a pathway for Cambrooke’s use of Ajinomoto’s core technologies on metabolic and ketogenic therapy products, as well as accelerated development of better nutritional solutions for more chronic conditions.
About Ajinomoto North America, Inc.
Ajinomoto North America, Inc. is a wholly owned subsidiary of Ajinomoto Co., Inc. and is a recognized global leader in the research, development, manufacture and sale of amino acid-based products for the pharmaceutical, nutraceutical, sports nutrition, health and beauty industries as well as food ingredients and consumer food products. The company opened its first American office in New York in 1917 and has since grown and expanded its presence, establishing offices and production facilities in North Carolina, Iowa and Illinois. Ajinomoto North America, Inc. leverages an international manufacturing, supply and distribution chain to bring the highest-grade products to customers.
About Cambrooke Therapeutics
Founded in 2000, Cambrooke is a Massachusetts-based therapeutic nutrition company and global provider of medical nutrition products for patients with serious, chronic, unmet medical needs. The company works with physicians and researchers from around the world to develop, test and commercialize products that are today focused on inborn errors of metabolism and intractable epilepsy.
